Table 2 Comparative statistics of anti-MOG with demographic and clinical parameters.

From: Clinical characteristics of anti-myelin oligodendrocyte glycoprotein antibody among aquaporin-4 negative neuromyelitis optica spectrum disorders in Egyptian patients

 

Anti-MOG

 

Negative (n = 37)

Positive (n = 3)

P-value

Age (years)

Range

10

-

62

12

-

40

0.696

Mean ± SD

29.73

 ± 

12.89

26.66

 ± 

14.04

 

N

(%)

N

(%)

P-value

Gender

Male

12

(32.43)

3

(100)

0.232

Female

25

(67.57)

0

(0)

Risk factors

Smoking

3

(8.11)

0

(0.00)

0.608

FH of MS

0

(0.00)

0

(0.00)

-

FH of Consanguinity

13

(35.14)

0

(0.00)

0.211

FH of Autoimmune disease

3

(8.11)

0

(0.00)

0.608

Relapses

No

25

(67.57)

2

(66.67)

0.974

Yes

12

(32.43)

1

(33.33)

Number of attacks

One

6

(50.00)

1

(100.0)0)

0.968

Two

2

(16.67)

0

(0.00)

Four

1

(8.33)

0

(0.00)

Five

1

(8.33)

0

(0.00)

Six

1

(8.33)

0

(0.00)

Eight

1

(8.33)

0

(0.00)

 

Type of attacks

Cranial nerves(optic)

8

(66.67)

1

(100.00)

0.488

Motor

4

(33.33)

0

(0.00)

Treatment during attack

Pulse steroids

7

(58.33)

1

(100.00)

0.713

IVIG

4

(33.33)

0

(0.00)

Mixed

1

(8.33)

0

(0.00)

Maintenance treatment

Methotrexate

2

(5.41)

0

(0.00)

0.826

Vitamins &Iron

21

(56.76)

3

(100.00)

Oral steroids

3

(8.11)

0

(0.00)

Azathioprine

6

(16.22)

0

(0.00)

MabThera™/Rituximab

5

(13.51)

0

(0.00)

  1. F.H.: Family history; IVIG: Intravenous immunoglobulin; MS: Multiple sclerosis.
  2. Significance was set at p < 0.05.
Back to article page